CCND2 and diffuse large B-cell lymphoma: In future, we will conduct further study of the efficacy of targeted molecular therapy that inhibits CCND2 expression combined with R-CHOP in patients with ABC-DLBCL, with a view to further improving the prognosis of patients with this disease.